Paraza Pharma Inc. is pleased to announce a recent joint publication that was coauthored with Repare Therapeutics.
Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ
Paraza Pharma Inc. is pleased to announce a recent joint publication that was coauthored with Repare Therapeutics.
Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ